Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Association between S100B Levels and Long-Term Outcome after Aneurysmal Subarachnoid Hemorrhage: Systematic Review and Pooled Analysis

  • Pui Man Rosalind Lai,

    Affiliation Department of Neurosurgery, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  • Rose Du

    rdu@partners.org

    Affiliation Department of Neurosurgery, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

Association between S100B Levels and Long-Term Outcome after Aneurysmal Subarachnoid Hemorrhage: Systematic Review and Pooled Analysis

  • Pui Man Rosalind Lai, 
  • Rose Du
PLOS
x

Abstract

S100 calcium binding protein B (S100B), a well-studied marker for neurologic injury, has been suggested as a candidate for predicting outcome after subarachnoid hemorrhage. We performed a pooled analysis summarizing the associations between S100B protein in serum and cerebrospinal fluid (CSF) with radiographic vasospasm, delayed ischemic neurologic deficit (DIND), delayed cerebral infarction, and Glasgow Outcome Scale (GOS) outcome. A literature search using PubMed, the Cochrane Library, and the EMBASE databases was performed to identify relevant studies published up to May 2015. The weighted Stouffer’s Z method was used to perform a pooled analysis of outcome measures with greater than three studies. A total of 13 studies were included in this review. Higher serum S100B level was found to be associated with cerebral infarction as diagnosed by CT (padj = 3.1 x 10−4) and worse GOS outcome (padj = 5.5 x 10−11). There was no association found between serum and CSF S100B with radiographic vasospasm or DIND. S100B is a potential prognostic marker for aSAH outcome.

Introduction

Subarachnoid hemorrhage (SAH) secondary to the rupture of an intracranial aneurysm remains a major cause of morbidity and mortality[1]. While aneurysmal rupture and recurrent hemorrhage contribute to a high initial mortality rate, delayed neurologic deterioration from ischemic complications continues to be a significant contributor to patient disability[2].

Cerebral vasospasm has largely accounted for a patient’s clinical deterioration and has been the major focus of clinical research. Radiographic evidence of vasospasm is observed in up to 67% of patients after aneurysmal SAH (aSAH)[3, 4]. Vasospasm as seen on an arteriogram may begin as soon as 2–3 days after SAH, peaking at 7–10 days and lasting up to 2 weeks[5]. While there is a high prevalence of radiographic vasospasm, only 20–30% of patients with vasospasm develop clinical deteriorations[3, 4, 6]. Recent trials have also failed to improve outcome from the reversal of vasospasm, suggesting that the pathophysiology may be more complex than radiographic vasospasm alone[7]. Thus, a new term has been introduced to describe the clinical decline, delayed cerebral ischemia, which is defined as focal neurological or cognitive deficits (delayed ischemic neurologic deficit, DIND), and/or the appearance of a new infarction on computed tomography (CT) or magnetic resonance (MR) imaging attributable to cerebral vasospasm (delayed cerebral infarction).

Various mechanisms have been proposed to identify the pathophysiologic mechanism of delayed cerebral ischemia. Early brain injury is a newly proposed concept which postulates that poor outcome after aSAH is a result of global ischemic injury to the brain[8, 9]. After the initial SAH, early brain injury involving inflammation, blood brain barrier disruption and increased intracranial pressure result in global ischemic injury and subsequent neurologic decline. As more research points to other mechanisms as the focus in delayed cerebral ischemia, prognostic and therapeutic targets have been shifted to these new directions.

Protein S100B is a calcium-binding protein expressed predominantly in astroglial cells and has been a well-studied marker for traumatic and ischemic injury. Serum S100B has also emerged as a potential candidate marker of the disruption of the blood brain barrier[10]. Given the relationship between global ischemic injury and clinical deterioration, it has been proposed that the same relationship may exist with S100B level and aSAH outcome[11, 12]. In the past decade, studies have attempted to investigate the association of S100B level in aSAH with the development of radiographic or clinical vasospasm[11, 12]. Meta-analyses have been useful tools in integrating findings from multiple studies to demonstrate genetic and molecular associations with cerebral vasospasm and SAH outcome. [13, 14] The goal of this study is to summarize the findings and perform a comprehensive review and pooled analysis that examine the associations between serum and cerebrospinal fluid (CSF) S100B with long-term patient outcome, radiographic vasospasm, DIND and delayed cerebral infarction.

Methods

The following databases were used in a literature search for S100B with cerebral vasospasm, delayed cerebral ischemia or SAH outcome in humans published prior to May 2015: PubMed, the Cochrane Library, and EMBASE. Medical subject heading (MeSH) terms were used to identify studies containing the following subject terms: (“S100B” or “serum S100B” or “S100 calcium-binding protein beta subunit”) and (“cerebral vasospasm” or “intracranial vasospasm” or “delayed cerebral ischemia” or “DCI” or “delayed ischemic neurological deficits” or “DIND” or “delayed cerebral infarction”) and (“SAH” or “subarachnoid hemorrhage” or “aneurysmal subarachnoid hemorrhage” or “aneurysm”). The references of articles were also manually checked to search for additional studies.

The inclusion criteria were as follows: 1) retrospective or prospective cohort design, 2) statistical analysis with reporting of raw data, odds ratios with 95% confidence intervals or p values. Studies were excluded if they were identified as non-human studies, abstracts, case reports, commentaries, editorials or manuscripts unrelated to the research topic. Vasospasm or SAH not clearly due to a ruptured aneurysm were also excluded. If multiple measurements of S100B levels were independently reported in the same study, for example on day 0 and day 7 following ictus, the earliest timeframe measured was selected for the analysis.

Four parameters were assessed as outcome measures: radiographic vasospasm, DIND, delayed cerebral infarction, and Glasgow Outcome Scale (GOS) outcome. Each outcome measure was analyzed for both CSF and serum S100B independently. Radiographic vasospasm was defined as the narrowing of cerebral vessels visualized on diagnostic cerebral angiogram (DSA), computed tomography angiogram (CTA), or flow studies on Transcranial Doppler (TCD). DIND was defined as new onset of focal neurological deficit or deterioration in level of consciousness with no known intracerebral hemorrhage, rebleeding, or hydrocephalus, with or without radiographic evidence of vasospasm. Studies which defined vasospasm as clinical deterioration in addition to radiographic vasospasm were included under both radiographic vasospasm and DIND. Delayed cerebral infarction was classified as any new hypodensity in a vascular distribution on CT or MR imaging not seen on initial CT that is attributed to delayed cerebral ischemia. Patient outcome was defined as favorable (GOS 4–5) or unfavorable (GOS 1–3) from discharge to one-year followup. If GOS was measured at various time points within one study, values from the last followup was used in our analysis.

The following data were extracted from each study by both authors: author, year of publication, study size, sex and mean age of subjects, serum and CSF S100B levels, and the four outcome measures (radiographic vasospasm, DIND, delayed cerebral infarction, and Glasgow Outcome Scale (GOS).

Statistical analysis was performed using Review Manager (RevMan) version 5.3. The most commonly reported statistics were unpaired two-tailed or Mann-Whitney U tests with p values. A p value of 1 was assigned when studies reported non-significant findings with no exact p values available. Studies were excluded if no statistical method was described. All extracted p values were converted to one-tailed p values, and Stouffer’s Z method was used to perform pooled analyses for all 4 outcome measures. The weighted Stouffer’s Z method, or the Liptak-Stouffer test, is a validated tool in combining p values from independent tests and uses the square root of the sample size for the weighting [15]. A p value of 0.99 was used instead of p = 1 to avoid generating an infinite Z-score in the Stouffer’s test. The Benjamini and Hochberg correction was used to account for multiple testing. P < 0.05 was considered significant.

Results

A total of 161 studies were identified after removal of duplicate records (N = 15). Seventy-seven papers were identified for full-text assessment after the removal of non-human studies (n = 31), reviews, commentaries and meta-analyses (n = 11), and those studies that were unrelated to S100B (n = 42) (Fig 1). An additional 64 studies were excluded that were unrelated to aneurysmal subarachnoid hemorrhage, resulting in a final set of 13 records. The years of the studies included in this analysis ranged from 1997 to 2014.

The quality assessment of studies included in the pooled analyses is presented in S1 Table. Quality of each study was assessed based on external validity, internal validity, methods and statistical approach.

Study characteristics are detailed in Table 1. The thirteen studies included only cases of aSAH. All studies were written in English. A total of 575 patients were included with a mean age of 54.4 and 64% were female. Interventions in studies included surgical clipping alone, endovascular coiling alone and both. Two studies did not describe therapeutic procedures for aneurysms.

thumbnail
Table 1. Basic characteristics of the 13 studies included in the systematic review.

https://doi.org/10.1371/journal.pone.0151853.t001

A summary of the studies describing the method of S100B detection and outcome measures evaluated are described in Table 2. All CSF and serum samples were collected within 2 weeks following ictus. Eight studies evaluated radiographic vasospasm confirmed by CTA, DSA or TCD and three studies included clinical deterioration as the definition of symptomatic vasospasm or DIND. Delayed cerebral infarction by CT was detailed in 5 studies. A total of 10 studies used GOS as outcome measurements within 1 year after discharge.

thumbnail
Table 2. Summary of the literature on CSF and serum S100B as biomolecular markers for radiographic vasospasm, DIND, delayed cerebral infarction and GOS outcome after aneurysmal SAH.

https://doi.org/10.1371/journal.pone.0151853.t002

Pooled analysis was performed when there were more than three studies representing an outcome measure. The one-sided p value for each study was obtained (Table 3). Overall results for the pooled analyses are shown in Table 4. Each outcome measure is described in detail below.

thumbnail
Table 3. A total of 13 studies were included in this systematic review of S100B with radiographic vasospasm, DIND, delayed cerebral infarction, and GOS outcome.

Reported two-tailed p values were converted to one-tailed p value to perform the Stouffer’s method for pooled analysis.

https://doi.org/10.1371/journal.pone.0151853.t003

thumbnail
Table 4. Pooled analyses were performed for outcome measures with at least 3 studies represented.

https://doi.org/10.1371/journal.pone.0151853.t004

Evidence of radiographic vasospasm by DSA, TCD or CTA and its association with serum and CSF S100B was evaluated in 6[11, 1618, 20, 25] and 3[11, 17, 24] studies (Table 3), respectively. No association was found between serum or CSF S100B levels with radiographic vasospasm. Thus the pooled analysis also demonstrated no statistical significance (p = 1.0) (Table 4).

Three studies[11, 20, 25] evaluated the association between serum S100B level and neurologic deterioration attributed to ischemia (Table 3). Oertel et al. found lower levels of serum S100B to be associated with clinical deterioration[20], while the other two studies did not find this effect. The pooled analysis did not find an association between DIND with serum S100B (Table 4). There were no studies in our analysis that evaluated S100B in CSF with DIND.

Among the four studies[17, 18, 20, 23] examining the association between serum S100B with delayed cerebral infarction, three found higher levels to be associated with increased risk of infarction (Table 3). The pooled analysis summarized this finding with a significance at p = 1.0 x 10−4 (padj = 3.1 x 10−4). Pooled analysis was not generated for delayed cerebral infarction with CSF S100B as only two studies[17, 24] were included in this outcome, although both did not demonstrate a significant association.

Seven studies[17, 2023, 25, 26] met the criteria for evaluating serum S100B level with GOS outcome from the time of discharge up to one-year followup (Table 3). All studies reported higher serum S100B level with worse outcome. The pooled analysis summarized this association between serum S100B with worse clinical outcome (padj = 5.5 x 10−11). Four studies[12, 17, 19, 24] evaluated CSF S100B with clinical outcome. The pooled analysis suggests a trend towards higher S100B CSF level associating with worse GOS outcome but was not significant after multiple testing adjustment (p = 3.0x10-2, padj = 6.0 x 10−2).

Discussion

The identification of biomolecular markers for the prediction of outcome after aSAH has been widely studied. S100B is a member of the thirteen S100 calcium-binding family proteins of the EF hand motif, the most common calcium-binding motif in proteins[27]. S100B is primarily expressed in the cytoplasm of astrocytes and has been implicated in the regulation of cell cycle progression and differentiation through microtubule and intermediate filament assembly[28]. The protein was initially described in 1965 by Moore et al.[29] and subsequently, the alteration of S100B gene has been associated with many neurological diseases including Alzheimer’s, amyotrophic lateral sclerosis and epilepsy[3032]. More importantly, S100B has emerged as a marker of the acute phase of neurological damage. The protein is released by astrocytes following acute brain injury and can be detected in serum if the blood brain barrier is compromised. S100B has also been described as a prognostic marker in the prediction of outcome after traumatic brain injury and large volume cerebral infarction[3335]. Furthermore, an elevated serum S100B level has been demonstrated in ischemic stroke and is associated with worse outcome after a stroke[36, 37].

Weismann et al.[26] were the first to investigate the association between outcome after aSAH with S100B. They were also the first to report the measurement of S100B in serum as a potential non-invasive method to predict disease. The first published report to examine the association between radiographic vasospasm and S100B was by Oertel et al.[20] in 2006, albeit finding no correlation. Subsequently, more studies have tried to reexamine and replicate these studies to clarify the relationship between S100B with SAH outcome and vasospasm. The goal of our review and pooled analysis is to summarize these findings.

In this review, a total of 13 studies with 575 patients were identified in our literature search to analyze the association between serum and CSF S100B with radiographic vasospasm, DIND, delayed cerebral infarction and GOS outcome. There was a high association between elevated serum S100B level and cerebral infarction as demonstrated on CT. However, the temporal relationship between S100B levels and the appearance of infarctions on CT was not evaluated and the infarctions that are reported in the studies are not clearly non-treatment related. Thus the association here may simply be the result of brain injury regardless of cause. Indeed, a comparable relationship between serum S100B and ischemic stroke has been described in the literature. Hermann et al. found that increased serum S100B was associated with irreversible ischemic stroke, but not with reversible lesions[38]. It has been postulated that S100B is a marker signaling irreversible ischemic damage, thus explaining its correlation with infarction and subsequent worse long-term prognosis. Similarly, serum S100B may be a marker for infarction seen on CT secondary to severe vasospasm, but is not associated with reversible radiographic vasospasm. Given the current hypotheses of the complex mechanisms contributing to delayed cerebral ischemia, there may be other pathways independent of vasospasm which explain the increased serum S100B level and its relationship with ischemia despite its lack of association with radiographic vasospasm.

In addition to cerebral infarction, there is a high association between elevated serum S100B level and worse long-term GOS outcome. This association between S100B level and GOS outcome is already apparent at discharge, as both Jung et al. and Schick et al. described[18, 23]. Our pooled analysis included GOS outcome studies from discharge up to 1-year follow up, resulting in a total of 7 studies included in the evaluation for serum S100B. Despite the small sample sizes in each study, all described a similar relationship and positive correlation. Thus, the pooled analysis yielded a strong association. Delayed cerebral infarction with or without symptoms has been found to be a major predictor of poor outcome. Thus, it is not surprising that GOS outcome has an association with S100B, which is correlated with infarction itself[39]. There was a trend towards association between CSF S100B level and outcome, although it was not statistically significant in our study.

A number of limitations should be considered in this study. Although the weighted Stouffer’s method is a validated statistical approach to combine studies, many studies represented in this review did not include sufficient statistical information to perform a more rigorous pooled analysis. We were thus unable to assess heterogeneity and perform a meta-analysis using the random effects or fixed effects model. Despite this limitation, all studies reported higher S100B levels with worse clinical outcome, suggesting these effects are evident even with small sample sizes in each study. In contrast, no study demonstrated an association of radiographic vasospasm with S100B levels, suggesting strong evidence for a lack of association. However, the results for radiographic vasospasm are limited by the different criteria used in different studies (TCD based vs CTA/DSA based). Nevertheless, it has been shown that TCDs are highly specific for radiographic vasospasm as detected by DSA[40]. S100B levels have been reported to be higher after surgical clipping than endovascular coiling[25], but it was not possible to perform a subgroup analysis given the small number of studies. Future research stratifying the method of treatment may be helpful in further understanding this relationship.

Conclusions

Using a pooled analysis, we found higher serum S100B level to be associated with cerebral infarction and worse long-term outcome. However, we found no correlation with radiographic or clinical vasospasm. Further investigations of S100B may be helpful in validating the protein as a reliable predictor of long-term SAH outcome.

Supporting Information

S1 Table. Quality assessment of studies included in the pooled analyses.

https://doi.org/10.1371/journal.pone.0151853.s002

(DOCX)

Author Contributions

Conceived and designed the experiments: RD. Performed the experiments: PL. Analyzed the data: PL RD. Wrote the paper: PL RD.

References

  1. 1. King JT Jr. Epidemiology of aneurysmal subarachnoid hemorrhage. Neuroimaging clinics of North America. 1997;7(4):659–68. pmid:9336491.
  2. 2. Frontera JA, Fernandez A, Schmidt JM, Claassen J, Wartenberg KE, Badjatia N, et al. Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? Stroke; a journal of cerebral circulation. 2009;40(6):1963–8. pmid:19359629.
  3. 3. Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke; a journal of cerebral circulation. 1985;16(4):562–72. pmid:3895589.
  4. 4. Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I: Incidence and effects. J Clin Neurosci. 1994;1(1):19–26. Epub 1994/01/01. pmid:18638721.
  5. 5. Weir B, Grace M, Hansen J, Rothberg C. Time course of vasospasm in man. Journal of neurosurgery. 1978;48(2):173–8. pmid:624965.
  6. 6. Coyne TJ, Loch Macdonald R, Christopher Wallace M. Angiographic vasospasm in a contemporary series of patients with aneurysmal subarachnoid haemorrhage. J Clin Neurosci. 1994;1(2):106–10. pmid:18638739.
  7. 7. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). The Lancet Neurology. 2011;10(7):618–25. pmid:21640651.
  8. 8. Cahill J, Zhang JH. Subarachnoid hemorrhage: is it time for a new direction? Stroke; a journal of cerebral circulation. 2009;40(3 Suppl):S86–7. pmid:19064787; PubMed Central PMCID: PMC2743545.
  9. 9. Yuksel S, Tosun YB, Cahill J, Solaroglu I. Early brain injury following aneurysmal subarachnoid hemorrhage: emphasis on cellular apoptosis. Turkish neurosurgery. 2012;22(5):529–33. pmid:23015327.
  10. 10. Blyth BJ, Farhavar A, Gee C, Hawthorn B, He H, Nayak A, et al. Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. Journal of neurotrauma. 2009;26(9):1497–507. pmid:19257803; PubMed Central PMCID: PMC2822805.
  11. 11. Amiri M, Astrand R, Romner B. Can S100B Predict Cerebral Vasospasms in Patients Suffering from Subarachnoid Hemorrhage? Frontiers in neurology. 2013;4:65. pmid:23761779; PubMed Central PMCID: PMC3674401.
  12. 12. Kaneda K, Fujita M, Yamashita S, Kaneko T, Kawamura Y, Izumi T, et al. Prognostic value of biochemical markers of brain damage and oxidative stress in post-surgical aneurysmal subarachnoid hemorrhage patients. Brain research bulletin. 2010;81(1):173–7. pmid:19887101.
  13. 13. Ducruet AF, Gigante PR, Hickman ZL, Zacharia BE, Arias EJ, Grobelny BT, et al. Genetic determinants of cerebral vasospasm, delayed cerebral ischemia, and outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2010;30(4):676–88. pmid:20068580; PubMed Central PMCID: PMCPMC2949164.
  14. 14. Rosalind Lai PM, Du R. Role of Genetic Polymorphisms in Predicting Delayed Cerebral Ischemia and Radiographic Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis. World Neurosurg. 2015;84(4):933–41 e2. pmid:26074429.
  15. 15. Zaykin DV. Optimally weighted Z-test is a powerful method for combining probabilities in meta-analysis. Journal of evolutionary biology. 2011;24(8):1836–41. pmid:21605215; PubMed Central PMCID: PMC3135688.
  16. 16. Bellapart J, Jones L, Bandeshe H, Boots R. Plasma endothelin-1 as screening marker for cerebral vasospasm after subarachnoid hemorrhage. Neurocritical care. 2014;20(1):77–83. pmid:23921571.
  17. 17. Moritz S, Warnat J, Bele S, Graf BM, Woertgen C. The prognostic value of NSE and S100B from serum and cerebrospinal fluid in patients with spontaneous subarachnoid hemorrhage. Journal of neurosurgical anesthesiology. 2010;22(1):21–31. pmid:20027011.
  18. 18. Jung CS, Lange B, Zimmermann M, Seifert V. CSF and Serum Biomarkers Focusing on Cerebral Vasospasm and Ischemia after Subarachnoid Hemorrhage. Stroke research and treatment. 2013;2013:560305. pmid:23509668; PubMed Central PMCID: PMC3590649.
  19. 19. Kay A, Petzold A, Kerr M, Keir G, Thompson E, Nicoll J. Decreased cerebrospinal fluid apolipoprotein E after subarachnoid hemorrhage: correlation with injury severity and clinical outcome. Stroke; a journal of cerebral circulation. 2003;34(3):637–42. pmid:12624284.
  20. 20. Oertel M, Schumacher U, McArthur DL, Kastner S, Boker DK. S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome. J Clin Neurosci. 2006;13(8):834–40. pmid:16931022.
  21. 21. Pereira AR, Sanchez-Pena P, Biondi A, Sourour N, Boch AL, Colonne C, et al. Predictors of 1-year outcome after coiling for poor-grade subarachnoid aneurysmal hemorrhage. Neurocritical care. 2007;7(1):18–26. pmid:17657653.
  22. 22. Sanchez-Pena P, Pereira AR, Sourour NA, Biondi A, Lejean L, Colonne C, et al. S100B as an additional prognostic marker in subarachnoid aneurysmal hemorrhage. Critical care medicine. 2008;36(8):2267–73. pmid:18596638.
  23. 23. Schick U, Dohnert J, Meyer JJ, Vitzthum HE. Prognostic significance of SSEP, BAEP and serum S-100B monitoring after aneurysm surgery. Acta neurologica Scandinavica. 2003;108(3):161–9. pmid:12911458.
  24. 24. Siman R, Giovannone N, Toraskar N, Frangos S, Stein SC, Levine JM, et al. Evidence that a panel of neurodegeneration biomarkers predicts vasospasm, infarction, and outcome in aneurysmal subarachnoid hemorrhage. PloS one. 2011;6(12):e28938. pmid:22174930; PubMed Central PMCID: PMC3235169.
  25. 25. Weiss N, Sanchez-Pena P, Roche S, Beaudeux JL, Colonne C, Coriat P, et al. Prognosis value of plasma S100B protein levels after subarachnoid aneurysmal hemorrhage. Anesthesiology. 2006;104(4):658–66. pmid:16571959.
  26. 26. Wiesmann M, Missler U, Hagenstrom H, Gottmann D. S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta neurochirurgica. 1997;139(12):1155–60. pmid:9479422.
  27. 27. Moews PC, Kretsinger RH. Refinement of the structure of carp muscle calcium-binding parvalbumin by model building and difference Fourier analysis. Journal of molecular biology. 1975;91(2):201–25. pmid:1237625.
  28. 28. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. The international journal of biochemistry & cell biology. 2001;33(7):637–68. pmid:11390274.
  29. 29. Moore BW. A soluble protein characteristic of the nervous system. Biochemical and biophysical research communications. 1965;19(6):739–44. pmid:4953930.
  30. 30. Chaves ML, Camozzato AL, Ferreira ED, Piazenski I, Kochhann R, Dall'Igna O, et al. Serum levels of S100B and NSE proteins in Alzheimer's disease patients. Journal of neuroinflammation. 2010;7:6. pmid:20105309; PubMed Central PMCID: PMC2832635.
  31. 31. Otto M, Bahn E, Wiltfang J, Boekhoff I, Beuche W. Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis. Neuroscience letters. 1998;240(3):171–3. pmid:9502231.
  32. 32. Calik M, Abuhandan M, Sonmezler A, Kandemir H, Oz I, Taskin A, et al. Elevated serum S-100B levels in children with temporal lobe epilepsy. Seizure. 2013;22(2):99–102. pmid:23146618.
  33. 33. Thelin EP, Johannesson L, Nelson D, Bellander BM. S100B is an important outcome predictor in traumatic brain injury. Journal of neurotrauma. 2013;30(7):519–28. pmid:23297751.
  34. 34. Egea-Guerrero JJ, Murillo-Cabezas F, Gordillo-Escobar E, Rodriguez-Rodriguez A, Enamorado-Enamorado J, Revuelto-Rey J, et al. S100B protein may detect brain death development after severe traumatic brain injury. Journal of neurotrauma. 2013;30(20):1762–9. pmid:23710646; PubMed Central PMCID: PMC3796324.
  35. 35. Rainey T, Lesko M, Sacho R, Lecky F, Childs C. Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) time-point. Resuscitation. 2009;80(3):341–5. pmid:19150161.
  36. 36. Weglewski A, Ryglewicz D, Mular A, Jurynczyk J. [Changes of protein S100B serum concentration during ischemic and hemorrhagic stroke in relation to the volume of stroke lesion]. Neurologia i neurochirurgia polska. 2005;39(4):310–7. pmid:16096936.
  37. 37. Kaca-Orynska M, Tomasiuk R, Friedman A. Neuron-specific enolase and S 100B protein as predictors of outcome in ischaemic stroke. Neurologia i neurochirurgia polska. 2010;44(5):459–63. pmid:21082487.
  38. 38. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke; a journal of cerebral circulation. 2000;31(11):2670–7. pmid:11062293.
  39. 39. Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke; a journal of cerebral circulation. 2007;38(8):2315–21. pmid:17569871.
  40. 40. Sloan MA, Haley EC Jr., Kassell NF, Henry ML, Stewart SR, Beskin RR, et al. Sensitivity and specificity of transcranial Doppler ultrasonography in the diagnosis of vasospasm following subarachnoid hemorrhage. Neurology. 1989;39(11):1514–8. pmid:2682350